Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments

Table 5 Biomarker and genomic findings by hormone receptor and HER2 status

Hormone and HER2 status*	Pathogenic variant	Number of patients	Line of chemotherapy^†	Number of pathogenic variants^†	Number of VUS^†	TMB score^† (muts/Mb)
HR(-), HER2(-)	TP53	7	2 (0–3)	5.5 (2–9)	9 (2–20)	5 (5–11)
	MYC	3
	PIK3CA	3
	PTEN	3
HR(+), HER2(-)	PIK3CA	6	1 (0–4)	4 (1–11)	6.5 (3–13)	3 (0–10)
HR(+), HER2(-)	CDH1	3	1 (0–4)	4 (1–11)	6.5 (3–13)	3 (0–10)
P value			0.2124	0.703	0.336	0.030

* ER(-) plus PgR(-) was described as HR(-). ER(+), regardless of PgR status, was described as HR(+)
^†Medians (range). The HR(-), HER2(-) group had 8 patients. The HR(+), HER2(-) group had 14 patients
VUS: variants of unknown significance. TMB: tumor mutational burden

ISSN: 1471-2407